Small Molecules
10 October 2019
EicOsis Announces FDA Acceptance of IND Application for EC5026, the First Soluble Epoxide Hydrolase Inhibitor to Treat Pain8 October 2019
Yumanity Therapeutics Initiates Phase 1 Clinical Trial of Lead Candidate YTX-7739 for the Treatment of Parkinson’s Disease5 October 2019
Catabasis Pharmaceuticals Presents Edasalonexent, a Potential Foundational Treatment for Duchenne Muscular Dystrophy4 October 2019
Fulcrum Therapeutics Announced Results of Phase 1 Clinical Trial of Losmapimod in FSHD4 October 2019
Milestone Pharmaceuticals Announces First Patient Enrolled in NODE-303 Open-label Safety Study of Etripamil in PSVT4 October 2019
Graybug Vision Initiates Phase 2b (ALTISSIMO) Clinical Trial of GB-102 in Patients with Wet Age-Related Macular Degeneration4 October 2019
U.S. Food and Drug Administration Approves Descovy® for HIV Pre-Exposure Prophylaxis (PrEP)3 October 2019
Athira Pharma Announces Completion of Phase 1b Clinical Trial of NDX-1017 in Alzheimer’s Patients3 October 2019
Risdiplam Spinal Muscular Atrophy Data Demonstrating Continued Benefit Presented at World Muscle Society Congress2 October 2019
Shionogi Reports Positive Results from Cefiderocol Phase III Study in Adults with Pneumonia Caused by Gram-negative Pathogens2 October 2019
Update on US regulatory review of PT010 in COPD1 October 2019
Lilly Announces Positive Registrational Data for Selpercatinib (LOXO-292) in Heavily Pretreated RET-Altered Thyroid CancersNews Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
SubscribeNewsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
SubscribeFeatured reports